News - Astellas Pharma, Licensing

Filter

Current filters:

Astellas PharmaLicensing

Popular Filters

Cumberland Pharma acquires Vaprisol from Astellas

03-03-2014

USA-based Cumberland Pharmaceuticals says it has acquired from the US subsidiary of Japan’s Astellas…

Astellas PharmaCumberland PharmaceuticalsHematologyLicensingNorth AmericaPharmaceuticalUSAVaprisol

Astellas amends license deal for isavuconazole with Basilea

01-03-2014

Japanese drug major Astellas Pharma has amended the license, co-development and co-promotion agreement…

Antibiotics and Infectious diseasesAstellas PharmaBasilea PharmaceuticaCanadaisavuconazoleLicensingNorth AmericaPharmaceuticalUSA

AVEO and Astellas finally terminate tivozanib collaboration

14-02-2014

US biotech firm AVEO Oncology and Japanese drug major Astellas Pharma are to end their worldwide collaboration…

Astellas PharmaAVEO OncologyBiotechnologyLicensingOncologytivozanib

Astellas links with Mitokyne on mitochondria-related therapies

Astellas links with Mitokyne on mitochondria-related therapies

07-10-2013

Japanese drug major Astellas Pharma and USA-based start-up Mitokyne have entered into an exclusive R&D…

Astellas PharmaFinancialLicensingMergers & AcquisitionsMitokynePharmaceuticalResearch

Merck & Co to co-promote diabetes agent ipragliflozin in Japan

02-09-2013

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

AstraZeneca to fork out $815 million for rights to anemia drug candidate

31-07-2013

In yet another move to boost its R&D pipeline, Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered…

Asia-PacificASP1517Astellas PharmaAstraZenecaBiotechnologyFG-4592FibroGenLicensingNephrology and HepatologyNorth AmericaPharmaceuticalResearch

Seattle Genetics takes up option to co-develop additional ADC with Astellas

28-06-2013

Japanese drug major Astellas Pharma (TYO: 4503) says that US biotech firm Seattle Genetics (Nasdaq: SGEN)…

ASG-15MEAstellas PharmaBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

Astellas and Cytokinetics collaborate on new frontier of muscle biology

26-06-2013

In a second deal announced this month by US biotech firm, Cytokinetics (Nasdaq: CYTK) has entered into…

Astellas PharmaBiotechnologyCK-2127107CytokineticsLicensingPharmaceuticalResearch

Drais Pharma to develop third Astellas compound through Tacurion

08-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based Drais Pharmaceuticals have entered into…

ASP7035Astellas PharmaDrais PharmaceutialsGenito-urinaryLicensingPharmaceuticalResearchTacurion

Astellas and Ambrx collaborate in up to $300 oncology deal; Teijin takes stake in Kyorin

05-04-2013

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with venture capital…

AmbrxAstellas PharmaKyorin PharmaceuticalsLicensingMergers & AcquisitionsOncologyPharmaceuticalTeijin

Astellas ends FLT3 deal with Ambit; reports on flu vaccine ASP7374

12-03-2013

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) and USA-based privately held firm…

Ambit BiosciencesASP7374Astellas PharmaLicensingOncologyPharmaceuticalquizartinibResearchVaccines

Clinigen and Theravance deal on Vibativ; Cubist expands rights to ceftolozane

12-03-2013

UK-based Clinigen Group (LSE: CLIN ) and Theravance (Nasdaq: THRX) of the USA have entered into an exclusive…

Antibiotics and Infectious diseasesAstellas PharmaceftolozaneClinigen GroupCubist PharmaceuticalsEuropeGlobalLicensingPharmaceuticalTheravanceVibativ

Merck & Co in Nanobody deal with Ablynx; J&J and Astellas join forces on RA

02-10-2012

US pharma giant Merck & Co (NYSE: MRK) has entered into a collaboration with Belgium's Ablynx (Euronext…

AblynxAnti-Arthritics/RheumaticsASPO15KAstellas PharmaBiotechnologyJohnson & JohnsonLicensingMerck & CoPharmaceutical

Optimer earns 10 million-euro milestone as Astellas debuts Dificlir in Europe

11-06-2012

USA-Based Optimer Pharmaceuticals (Nasdaq: OPTR) says that it is set to receive 10 million euros ($12.5…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropeFinancialLicensingOptimer PharmaceuticalsPharmaceutical

Astellas partners with Drais to develop its ulcerative colitis compound

01-05-2012

apanese drug major Astellas Pharma (TYO: 4503) has entered into a uniquely structured partnership with…

Astellas PharmaDrais PharmaceutialsGastro-intestinalsLicensingPharmaceuticalTelsar Pharma

Optimer Pharma could earn $90 million from new Astellas deal

30-03-2012

US firm Optimer Pharmaceuticals (Nasdaq: OPTR) has entered into a second deal with Japanese drug major…

Antibiotics and Infectious diseasesAsia-PacificAstellas PharmaDificidfidaxomicinLicensingOptimer PharmaceuticalsPharmaceutical

UCB links with Astellas for Cimzia in Japan

02-02-2012

Following the recent discontinuation of a commercialization accord for its rheumatoid arthritis drug…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmaCimziaLicensingPharmaceuticalUCB

Astellas pulls out of deal with Theravance

09-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) says it has exercised its right to terminate the global…

Antibiotics and Infectious diseasesAstellas PharmaLicensingPharmaceuticalTheravanceVibativ

Astellas in-licenses antibody from Evec; Mitsubishi Tanabe deal with Synageva

06-09-2011

Japanese biotech firm Evec has entered a license agreement for one of its fully-human antibodies against…

Asia-PacificAstellas PharmaBiotechnologyEvecImmunologicalsLicensingMitsubishi TanabePharmaceuticalRare diseasesResearchSynageva BioPharma

Teijin and Astellas expand collaboration on gout drug febuxostat

12-08-2011

Japanese drugmakers Teijin Pharma (TYO: 3401 and Astellas Pharma (TKO:4503) have entered into an exclusive…

Anti-Arthritics/RheumaticsAsia-PacificAstellas PharmafebuxostatLicensingPharmaceuticalTeijin

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top